Analysis shows udenafil significantly improves exercise capacity in Fontan patients with reduced baseline function

A newly published, post-hoc analysis of the landmark FUEL (Fontan Udenafil Exercise Longitudinal) Trial demonstrates that udenafil, a PDE5 inhibitor, significantly improves peak oxygen consumption (peak VO₂) in adolescents with single-ventricle congenital heart disease (SV-CHD) who have undergone the Fontan procedure and have reduced exercise capacity.